Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?
about
Drugs for treating urinary schistosomiasisSchistosomiasis vaccinesPreclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemicPilot-scale production and characterization of paramyosin, a vaccine candidate for schistosomiasis japonicaHelminth infections: the great neglected tropical diseasesPrime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccineCurrent status of vaccines for schistosomiasisAssessment of the age-specific disability weight of chronic schistosomiasis japonicaDevelopment of Paramyosin as a Vaccine Candidate for SchistosomiasisImmunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposureCloning and characterisation of Schistosoma japonicum insulin receptorsCytokine responses to the anti-schistosome vaccine candidate antigen glutathione-S-transferase vary with host age and are boosted by praziquantel treatmentDNA Vaccine Encoding the Chimeric Form of Schistosoma mansoni Sm-TSP2 and Sm29 Confers Partial Protection against Challenge InfectionVaccines to combat the neglected tropical diseases.The nature and combination of subunits used in epitope-based Schistosoma japonicum vaccine formulations affect their efficacy.Resistance to re-infection after exposure to normal and attenuated schistosome parasites in the baboon model.Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda.The schistosomiasis research agenda--what now?Schistosomiasis Japonica: The DALYs RecapturedDecision-model estimation of the age-specific disability weight for schistosomiasis japonica: a systematic review of the literature.Trick or treat: the role of vaccines in integrated schistosomiasis control.A wake up call for urinary schistosomiasis: reconciling research effort with public health importance.Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam.Complement plays a minimal role in Sm-p80-mediated protection against Schistosoma mansoni.Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine.Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice.Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2.T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum.Partial regulatory T cell depletion prior to schistosomiasis vaccination does not enhance the protectionCombined TLR7/8 and TLR9 ligands potentiate the activity of a Schistosoma japonicum DNA vaccine.Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).Local immune responses of the Chinese water buffalo, Bubalus bubalis, against Schistosoma japonicum larvae: crucial insights for vaccine design.Performance of a dipstick dye immunoassay for rapid screening of Schistosoma japonicum infection in areas of low endemicity.Proteomic analysis of schistosoma japonicum schistosomulum proteins that are differentially expressed among hosts differing in their susceptibility to the infection.Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection modelProtective Potential of Antioxidant Enzymes as Vaccines for Schistosomiasis in a Non-Human Primate Model.Having a pair: the key to immune evasion for the diploid pathogen Schistosoma japonicumA vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasisProspects for development of a transmission blocking vaccine against Schistosoma japonicum.
P2860
Q24241883-8ACFD559-6845-4F07-8BA3-3B3DB06D609FQ24598949-144FF948-0A7C-4C07-9CB0-1282A861D269Q24635389-B83BB55C-9B7A-4980-8EB0-12B20CCE021BQ24646962-3F9C456A-F487-471E-BA5E-CD0B6DB0EB7DQ24648324-2203C18D-11E8-405A-92F8-2B6502A11CE0Q24655529-647CE780-6351-4CA7-9454-C8E7805B45D6Q24657733-ECBDB42B-D5D2-4C19-B598-5BEC0FA447D7Q24657922-7D1367C1-F6AD-466F-933D-06ED9B6B8C9CQ26800164-BA6647CC-D780-4464-AFB0-5557A1347D46Q28471815-4BDA8234-EEA6-4E0F-9E26-462227CEFD3FQ28473411-E0D3CE34-F304-4418-93D7-55F116810C26Q28538582-57455CC0-28F0-4C73-880F-AEF5034E9022Q28547011-7BFC0091-A73B-4491-8405-276CC09E9389Q30425005-02C6573C-9826-40F5-AB82-91CC2126A19FQ30502461-B14B08C7-D2A1-4B93-9D5B-27DF9AC6C26BQ33222727-DF106381-7CD8-4C60-B6B6-C1CEECC6D2D1Q33296532-90BB16BE-E899-4D14-AADF-DC6F71734805Q33321217-BD6718ED-7CAE-49E6-95ED-1C435FFB8BB3Q33322505-2EA5D102-5C09-4802-921E-AE7227AE5CF0Q33322507-A5A944D9-16B9-463F-81E0-D321C5B7C3F9Q33346303-4C659829-CE81-4B10-BDF3-A8F9D41F3481Q33486179-C6EBB8B4-11B2-44BE-8793-A53CAAD3AD90Q33684408-D519274B-B21D-4BBB-99EC-5D04EE13F666Q33825627-EFA509AC-D186-4CEB-BFF2-87302CB3ED27Q34033792-A807127E-8D12-4120-86ED-7DD352C3768AQ34071134-3CD70A62-F56C-43D3-8224-006C9C9FF393Q34137896-D06A4DFD-637A-432B-A86E-941F49CC5702Q34201141-2276062F-B758-4DA4-B91B-8485B4FD087EQ34301170-BF31CEAA-1D76-4D82-924A-F146C89662D3Q34339707-DF5383FA-E1E3-41F5-B564-CAB06BE1F90CQ34675128-32B373F9-8B8B-4790-9F4B-D3254809F365Q34899535-B8377943-D20E-4B00-BB4E-3C6CB4AE1696Q35006539-4DA33A08-9E15-47A6-8337-3A5B1694AF12Q35068412-2178A76A-1610-4888-B13A-02C22A234475Q35144113-56A6E5E1-C012-475B-B84D-D72273D4D7CEQ35319744-211CB5AA-770F-4A4C-917D-1255AE44A968Q35665650-DD58DA2B-9693-463B-AF20-B4EEB2E6A50BQ35861537-94EDBFCE-9094-4F03-9A1E-30855F4D439BQ35946661-B7A23D45-CA7E-45A5-88AF-CABA8CF54F4FQ36247373-95C57E57-DF3B-4CF3-B633-09D8697F2119
P2860
Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Vaccine-linked chemotherapy: c ...... t from an integrated approach?
@ast
Vaccine-linked chemotherapy: c ...... t from an integrated approach?
@en
type
label
Vaccine-linked chemotherapy: c ...... t from an integrated approach?
@ast
Vaccine-linked chemotherapy: c ...... t from an integrated approach?
@en
prefLabel
Vaccine-linked chemotherapy: c ...... t from an integrated approach?
@ast
Vaccine-linked chemotherapy: c ...... t from an integrated approach?
@en
P2093
P356
P1476
Vaccine-linked chemotherapy: c ...... t from an integrated approach?
@en
P2093
Graham F Mitchell
Lydia R Leonardo
N Robert Bergquist
P304
P356
10.1016/J.PT.2005.01.001
P5008
P577
2005-03-01T00:00:00Z